Figure 9
From: Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers
In vivo anti-tumor effect of anti-Nectin-2 mAbs in the OV-90 mouse subcutaneous xenograft preventive model. OV-90 cells were subcutaneously inoculated into the flanks of nude mice. On the same day, Y-187 or Y-443 at a dose of 15 mg/kg or vehicle was intravenously administered on a biweekly basis to the mice. The results are mean ± S.D. or tumor volume. **: p < 0.001 versus the vehicle group determined by the Steel test.